Neurocrine price target raised to $175 from $165 at Guggenheim

Guggenheim analyst Yatin Suneja raised the firm’s price target on Neurocrine (NBIX) to $175 from $165 and keeps a Buy rating on the shares. Non-GAAP EPS came in above the Street’s forecast and the company narrowed FY25 Ingrezza sales guidance to $2.5-$2.55B, notes the analyst, who calls out the Phase 2 readout in MDD with NBI-770 and Phase 3 readouts in Dyskinetic Cerebral Palsy, both due in Q4, as the next key catalysts for Neurocrine.